
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
Beauty Health Co. has demonstrated strong growth in consumable revenue, which rose 18% to $46.4 million, while international sales experienced a significant increase of 51%, particularly in the APAC region, showcasing a robust expansion strategy. The company's installed base of HydraFacial devices grew by 23% year-over-year, indicating strong demand for its products, and market penetration in China is indicative of further growth potential. Additionally, projected annualized cost savings of over $15 million due to manufacturing optimization could enhance profitability, despite current challenges with product issues and special charges.
Bears say
The Beauty Health Company's recent financial performance has raised significant concerns, as the revenue of $97 million in 3Q23 substantially fell short of both internal estimates and market consensus, triggering a downward revision of 2023 sales guidance from $460-$480 million to $385-$400 million. The company also reported an adjusted EBITDA of $9.1 million, missing expectations by a considerable margin, while lowering its adjusted EBITDA margin outlook for the year to a drastically reduced 5-6% from the previously anticipated 18-19%. Furthermore, the suspension of long-term financial targets for 2025, alongside the departure of key executives and restructuring charges related to product issues, further underscores the challenges Beauty Health faces in attaining sustainable profitability and growth in a competitive market.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares